$NUVA (NuVasive, Inc.)

$NUVA {{ '2016-08-01T17:32:59+0000' | timeago}} • Announcement

$NUVA said it appointed Mike O'Halleran and Pat Miles to its BoD effective Aug. 1, 2016. Mr. O'Halleran will serve as an independent director of the company and member of the Board's Audit Committee. Mr. Miles, currently President and COO of $NUVA and a member of the company's executive management team, will serve as a non-independent Board member.

$NUVA {{ '2017-09-07T15:00:39+0000' | timeago}} • Announcement

$NUVA, a medical device company, has announced the acquisition of Vertera Spine, a privately-held firm developing and commercializing highly innovative interbody implants for spinal fusion using patented porous polyetheretherketone (PEEK) technology. Terms of the acquisition were not disclosed.

$NUVA {{ '2017-09-06T14:47:36+0000' | timeago}} • Announcement

$NUVA, a medical device company, got 510(k) clearance from the FDA for its redesigned MAGEC system with its RELINE Small Stature system. The MAGEC system uses innovative magnetic technology within adjustable growing rods to treat early-onset scoliosis in a less invasive manner.

$NUVA {{ '2017-08-15T12:38:20+0000' | timeago}} • Announcement

$NUVA appointed Rajesh J. Asarpota as the new executive Vice President and Chief Financial Officer, effective effective September 1, 2017. In this new role, Asarpota will be responsible for the company's global finance functions including accounting, FP&A, treasury and tax.

$NUVA {{ '2017-07-28T17:40:21+0000' | timeago}} • Announcement

Jason Hannon, President and COO of $NUVA, has stepped down and Matt Link, President of US Commercial, was promoted as EVP, Strategy and Corporate Development. Skip Kiil, EVP, International is the new EVP, Global Commercial. Steve Rozow, VP, Global Operations, becomes EVP. CFO Quentin Blackford’s resignation was accepted, effective Aug 25, 2017.

$NUVA {{ '2017-06-01T12:44:03+0000' | timeago}} • Announcement

$NUVA appointed Skip Kiil as EVP, International. In this role, Kiil will oversee the company's international operations, reporting to NuVasive's chairman and CEO, Gregory Lucier, and serving on the company's executive leadership team.

$NUVA {{ '2016-11-04T20:52:50+0000' | timeago}} • Announcement

$NUVA announced FDA clearance for magnetic resonance imaging (MRI) under certain conditions on patients treated with the innovative MAGEC system. MAGEC is the only noninvasive solution for growth modulation in pediatric spinal deformity cleared by the FDA.

$NUVA {{ '2016-09-19T19:35:19+0000' | timeago}} • Announcement

$NUVA, a medical device company, has received FDA 510(k) clearance for the its MAGEC system to be surgically implanted using its Reline posterior fixation system for treating patients with severe spinal deformity conditions.

$NUVA {{ '2016-09-13T10:56:19+0000' | timeago}} • Announcement

Medical device company $NUVA expects revenue to be about $962MM, non-GAAP diluted EPs to be about $1.64 and non-GAAP operating profit margin to be about 16% for full-year 2016.

$NUVA {{ '2016-09-13T10:56:12+0000' | timeago}} • Announcement

$NUVA said Jason Hannon, currently EVP, International, has been promoted to President and COO. Hannon succeeds Patrick Miles who has been appointed as Vice Chairman and will continue to serve as a member of the company's BoD.

$NUVA {{ '2016-08-01T17:32:59+0000' | timeago}} • Announcement

$NUVA said it appointed Mike O'Halleran and Pat Miles to its BoD effective Aug. 1, 2016. Mr. O'Halleran will serve as an independent director of the company and member of the Board's Audit Committee. Mr. Miles, currently President and COO of $NUVA and a member of the company's executive management team, will serve as a non-independent Board member.

$NUVA {{ '2016-07-05T13:09:44+0000' | timeago}} • Announcement

$NUVA said it has successfully completed acquisition of Biotronic NeuroNetwork, provider of intraoperative neurophysiological monitoring services. The company will provide an update to its FY16 outlook on its 2Q earnings conference call scheduled for July 26.

$NUVA {{ '2016-06-07T18:01:38+0000' | timeago}} • Announcement

$NUVA said it expects the transaction to meet its goals for return on invested capital, consistent with previously stated acquisition criteria. The transaction is expected to close in early July 2016. Bank of America Merrill Lynch is serving as exclusive financial advisor to $NUVA, and DLA Piper LLP (US) is serving as its legal counsel.

$NUVA {{ '2016-06-07T18:00:29+0000' | timeago}} • Announcement

$NUVA said it agreed to buy Biotronic NeuroNetwork for $98MM in cash. Both companies' BoD unanimously approved deal. $NUVA expects transaction to immediately add to its non-GAAP EPS in 2016 and significantly add in 2017 and beyond. $NUVA sees deal to support 2016 non-GAAP operating margin guidance of 15.8% and longer-term revenue growth forecast.

$NUVA {{ '2016-03-11T11:46:22+0000' | timeago}} • Announcement

Medical device company $NUVA announced the pricing of its offering of $550,000,000 aggregate principal amount of 2.25% Convertible Senior Notes due 2021 in a private placement to qualified institutional buyers. The sale to the initial purchasers is expected to settle on March 16, 2016 and is expected to result in $536MM in net proceeds to $NUVA.

$NUVA {{ '2016-03-08T10:04:15+0000' | timeago}} • Announcement

Medical device company $NUVA said it has agreed to acquire Mega Surgical, the exclusive distributor of $NUVA's products in Brazil. This acquisition will provide $NUVA with growth opportunities in the Latin American market. The transaction is expected to close in 1Q16. Terms of the transaction were not disclosed.

$NUVA {{ '2016-02-12T11:44:24+0000' | timeago}} • Announcement

Medical device company $NUVA said its BoD appointed Robert Friel and Donald Rosenberg as independent directors of the company, effective Feb. 12, 2016. These appointments expand $NUVA's Board from seven to nine directors, eight of whom are independent directors.

$NUVA {{ '2016-01-12T15:38:58+0000' | timeago}} • Announcement

$NUVA anticipates full year 2016 revenue growth of 7% YoverY to $870MM, in line with the mid to high single-digit long-term revenue growth target announced previously. Additionally, $NUVA anticipates full year 2016 non-GAAP operating profit margin expansion of approx. 100 BP vs. full year 2015, exclusive of the impact of the Ellipse acquisition.

$NUVA {{ '2016-01-12T15:38:11+0000' | timeago}} • Announcement

Global medical device company $NUVA said it expects preliminary full year 2015 revenue of approx. $811MM, reflecting a growth of 6% YoverY, or 8% on a constant currency basis. The company also anticipates preliminary 4Q15 revenue of approx. $215MM. Preliminary full year 2015 non-GAAP operating profit margin is expected to exceed guidance of 15.2%.

$NUVA {{ '2015-12-11T11:06:18+0000' | timeago}} • Announcement

Medical device company $NUVA said it has selected a site for its new medical device facility committed to spinal implant and instrument manufacturing in West Carrollton, Ohio. The company agreed to acquire this manufacturing site and plans to invest approx. $45MM over the next 24 months to build-out and equip the 160,000 square foot new facility.

$GE {{ '2015-12-01T13:01:22+0000' | timeago}} • Announcement

The spinal device maker $NUVA appointed Jason Hanson as EVP, Strategy, Corporate Development and General Counsel. Hanson joins $NUVA from $GE where he was Corporate VP and member of the senior executive team at GE Healthcare. His career includes law firm, government and corporate experience.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
RTIX (RTI Surgical Inc.)
Tuesday, August 8 2017 - 12:30pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
SHPG (Shire plc)
Thursday, August 3 2017 - 1:00pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, August 3 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, August 3 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, August 2 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, August 2 2017 - 8:30pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
NUVA (NuVasive, Inc.)
Thursday, July 27 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
BAX (Baxter International Inc.)
Wednesday, July 26 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm

AlphaGraphics you may like